On April 28, Guiyang Xintian Pharmaceutical Co.Ltd(002873) disclosed the first quarter report of 2022. In the first quarter of 2022, the company achieved an operating revenue of 249 million yuan, a year-on-year increase of 16.10%; The net profit was 30.88 million yuan, a year-on-year increase of 21.73%.
The first quarterly report shows that the social security fund appears in the top ten shareholders for the first time; Compared with the end of 2021, Wanjia fund significantly increased its holdings, and its growth optimization fund, one-year domestic demand growth fund, health industry fund, three-year science and innovation theme fund and other funds appeared in the list of the top ten shareholders.
For the impact of the epidemic since this year, the company said that although the prescription drug sales and OTC sales, logistics and distribution in some regions of the company have been affected to some extent, the normal growth trend has remained unchanged this year. In the first quarter, the company achieved an operating revenue of 249 million yuan and completed 20.77% of the equity incentive target (1.2 billion yuan). The proportion of revenue in the first quarter in the whole year was basically the same as that in the historical year; The impact of the epidemic on the achievement of this year’s annual performance growth target is still controllable, and the annual growth trend of the company remains unchanged. For the impact of the epidemic, the company has reduced the impact of the epidemic on the achievement of the annual goal by increasing OTC and online publicity and promotion, focusing on strengthening the promotion in non epidemic areas, and appropriately adjusting sales arrangements and logistics plans.
Guiyang Xintian Pharmaceutical Co.Ltd(002873) relevant person in charge said that the company has a solid foundation of product power and strong channel ability: first, the product has rich long-term clinical evidence and accurate curative effect; Second, the main products are exclusive varieties in China, and are the products of the national catalogue of basic drugs and medical insurance, which has a good market foundation; Third, the main products have opened up the dual channel marketing of prescription drugs and OTC, and have a relatively mature structure and team in channel construction and maintenance; Fourth, the company is rapidly promoting the implementation of “brand strategy” as planned, greatly increasing the investment in brand promotion and enhancing the brand influence of products.
